Prosecution Insights
Prosecution Insights
8 pending office actions • 2 clients • 8 examiners • 7 art units • 0 of 8 (0%) have an AI response strategy ready • 29 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (62%) |
| No statute on record | 3 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, PO-CHIH | 1 | 74.7% | +13.9% |
| REDDIG, PETER J | 1 | 58.0% | +40.0% |
| REDWOOD, CHRISTOPHER EVAN | 1 | — | — |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.3% | +48.6% |
| NATARAJAN, MEERA | 1 | 62.2% | +16.8% |
| JARRELL, NOBLE E | 1 | 81.3% | +9.0% |
| VALLE, ERNESTO | 1 | 60.0% | +33.3% |
| MOORE, SUSANNA | 1 | 68.1% | +31.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18179838 | SOLID FORMS, SALTS, AND PROCESSES OF PREPARATION OF A CDK2 INHIBITOR | TOWNSLEY, SARA ELIZABETH | 28d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18824281 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | CHEN, PO-CHIH | 295d overdue |
| 18179838 | SOLID FORMS, SALTS, AND PROCESSES OF PREPARATION OF A CDK2 INHIBITOR | TOWNSLEY, SARA ELIZABETH | 28d overdue |
| 17674237 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | MOORE, SUSANNA | 9d overdue |
| 17991482 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR | VALLE, ERNESTO | 7d |
| 18162955 | COMBINATION OF AN ANTI-CD19 ANTIBODY AND A BRUTON'S TYROSINE KINASE INHIBITOR AND USES THEREOF | NATARAJAN, MEERA | 26d |
| 18373648 | ANTI-PD-1/LAG-3 BISPECIFIC ANTIBODIES AND USES THEREOF | REDDIG, PETER J | 27d |
| Client (Assignee) | Pending OAs |
|---|---|
| Incyte | 7 |
| Incyte Holdings Corporation | 1 |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1621 | 1 |
| 1646 | 1 |
| 1643 | 1 |
| 1699 | 1 |
| 1623 | 1 |
| 1624 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18824281 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | Incyte Corporation | CHEN, PO-CHIH | 1621 | §103 | Non-Final OA | 295d overdue | Pending | Sep 04, 2024 |
| 18373648 | ANTI-PD-1/LAG-3 BISPECIFIC ANTIBODIES AND USES THEREOF | Incyte Corporation | REDDIG, PETER J | 1646 | Other | Non-Final OA | 27d | Pending | Sep 27, 2023 |
| 18232970 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | Incyte Corporation | REDWOOD, CHRISTOPHER EVAN | 1629 | §103 | Non-Final OA | 25d overdue | Pending | Aug 11, 2023 |
| 18179838 | SOLID FORMS, SALTS, AND PROCESSES OF PREPARATION OF A CDK2 INHIBITOR | Incyte Corporation | TOWNSLEY, SARA ELIZABETH | 1629 | §103 | Non-Final OA | 28d overdue | Pending | Mar 07, 2023 |
| 18162955 | COMBINATION OF AN ANTI-CD19 ANTIBODY AND A BRUTON'S TYROSINE KINASE INHIBITOR AND USES THEREOF | Incyte Corporation | NATARAJAN, MEERA | 1643 | §103 | Final Rejection | 26d | Pending | Feb 01, 2023 |
| 18092610 | PD-L1/STING CONJUGATES AND METHODS OF USE | Incyte Corporation | JARRELL, NOBLE E | 1699 | Other | Non-Final OA | 51d overdue | Pending | Jan 03, 2023 |
| 17991482 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR | Incyte Corporation | VALLE, ERNESTO | 1623 | §103 | Final Rejection | 7d | Pending | Nov 21, 2022 |
| 17674237 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | Incyte Holdings Corporation | MOORE, SUSANNA | 1624 | Other | Final Rejection | 9d overdue | Pending | Feb 17, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial